ERBB2 and breast carcinoma: An earlier study proposed that interleukin-6 family cytokines can be used as profiling biomarkers for HER2− breast cancer tissues, particularly in cases of triple-negative breast cancer, but they had no significant association with HER2+ cancer tissues (Niu et al., 2002).